Impact of National Omicron Outbreak at the end of 2022 on the future outlook of COVID-19 in China

References

• Araf Y, Akter F, Tang Y-D, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825–1832.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603(7902):700–705.
   PubMed Web of Science ®Google Scholar
• Bureau CsB. China says 80% of population have had Covid-19, as millions travel for Lunar New Year. Cable News Network. 2023 January 22 [cited 2023, Feb 23]. Available from: https://edition.cnn.com/2023/01/22/china/china-covid-80-lunar-new-year-intl-hnk/index.html.
   Google Scholar
• McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–1443.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang L, Feng Z, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. 2023.
   PubMed Web of Science ®Google Scholar
• de La Vega M-A, Polychronopoulou E, Ara, et al. SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants. Emerg Microbes Infect. 2023: 2169198.
   Web of Science ®Google Scholar
• Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023.
   PubMed Web of Science ®Google Scholar
• Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023;614(7948):521–529.
   PubMed Web of Science ®Google Scholar
• Qu P, Evans JP, Faraone JN, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31(1).
   PubMed Web of Science ®Google Scholar
• Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2).
   Web of Science ®Google Scholar
• Yue C, Song W, Wang L, et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23(3):278–280.
   PubMed Web of Science ®Google Scholar
• Our World in Data [Internet]. Johns Hopkins University. 2020 [cited 2023, Feb 23]. Available from: https://ourworldindata.org/coronavirus.
   Google Scholar
• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
   PubMed Web of Science ®Google Scholar
• Kandeel M, Mohamed MEM, Abd El-Lateef HM, et al. Omicron variant genome evolution and phylogenetics. J Med Virol. 2022;94(4):1627–1632.
   PubMed Web of Science ®Google Scholar
• Zhao H, Meng X, Peng Z, et al. Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants. Emerg Microbes Infect. 2022;11(1):926–937.
   PubMed Web of Science ®Google Scholar
• COVID Data Tracker [Internet]. Atlanta, GA: US Department of Health and Human Services, CDC. [cited 2023, Feb 21]. Available from: https://covid.cdc.gov/covid-data-tracker.
   Google Scholar
• Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. bioRxiv. 2022.2022.12.27.521986.
   Google Scholar
• Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):89–91.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Ayoub HH, AlMukdad S, et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe. 2022;3(12):e944–e955.
   PubMedGoogle Scholar
• He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629–637.
   PubMed Web of Science ®Google Scholar
• Offit PA. Bivalent Covid-19 vaccines – A cautionary tale. N Engl J Med. 2023;388(6):481–483.
   PubMed Web of Science ®Google Scholar
• Gao B, He L, Bao Y, et al. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection. Cell Res. 2023;33(3):258–261.
   PubMed Web of Science ®Google Scholar
• Stein C, Nassereldine H, Sorensen RJD, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833–842.
   PubMed Web of Science ®Google Scholar